v3.25.2
Share-Based Compensation and Other Compensation Plans (Tables)
3 Months Ended
Jun. 30, 2025
Share-Based Compensation and Other Compensation Plans [Abstract]  
Activity for Stock Options and Performance Stock Options
Activity for stock options and performance stock options under the RSL Equity Plans for the three months ended June 30, 2025 was as follows:
 
   
Number of Options
 
Options outstanding at March 31, 2025
   
139,412,098
 
Granted
   
1,976,147
 
Exercised
   
(5,481,656
)
Forfeited/Canceled
   
(313,373
)
Options outstanding at June 30, 2025
   
135,593,216
 
Options exercisable at June 30, 2025
   
113,027,137
 
Activity for RSUs
Activity for RSUs under the RSL Equity Plans for the three months ended June 30, 2025 was as follows:
 
   
Number of RSUs
 
Non-vested balance at March 31, 2025
   
14,119,949
 
Granted
   
4,097,713
 
Vested
   
(1,605,772
)
Forfeited
   
(373,237
)
Non-vested balance at June 30, 2025
   
16,238,653
 
Activity for Capped Value Appreciation Rights
Activity for CVARs granted in November 2021 under the RSL 2021 EIP for the three months ended June 30, 2025 was as follows:
 
   
Number of CVARs
 
Non-vested balance at March 31, 2025
   
348,527
 
Vested
   
(297,795
)
Forfeited
   
(50,732
)
Non-vested balance at June 30, 2025
   
 
One-time Cash Retention Awards Pursuant to the 2024 Senior Executive Compensation Program, the Compensation Committee of the board of directors approved the following one-time cash retention awards in July 2024:
Executive
 
Title
 
Cash Awards
(in thousands)
 
           
Matthew Gline
 
Chief Executive Officer
 
$
5,725
 
Mayukh Sukhatme
 
President and Chief Investment Officer
 
$
80,550
 
Eric Venker
 
President and Immunovant CEO
 
$
7,465